Turning Point Therapeutics, a San Diego-based developer of targeted cancer drugs, is presenting updated data Friday showing that its targeted therapy helps lung cancer patients whose disease is driven by a rare genetic alteration.

The drug, repotrectinib, has been tested in 33 patients whose cancer is driven by an alteration of a gene called ROS1. Eleven of these patients have not previously been treated with another drug; of these, nine, or 82%, saw their tumors shrink by at least 30%. (Doctors call this shrinkage a “response.”)

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy